Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Zai lab limited save search
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Published: 2024-01-10 (Crawled : 00:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.16%
H: 0.09%
C: -1.05%
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 0.38%
H: 1.24%
C: -2.14%
publication advanced
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 2.31%
H: 10.14%
C: 8.87%
granted tumors treatment designation china therapy
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Published: 2023-07-17 (Crawled : 05:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 8.26%
H: 0.5%
C: -8.33%
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: 25.96%
H: 4.43%
C: 1.45%
report vyvgart positive topline study
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -1.12%
H: 1.1%
C: 0.38%
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
Published: 2023-03-20 (Crawled : 23:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: -9.85%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 9.53%
H: 0.75%
C: -13.05%
positive schizophrenia emergent-3 trial therapeutics results
Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 16:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -1.73%
H: 0.38%
C: -3.24%
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Published: 2022-04-28 (Crawled : 21:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 0.54%
H: 1.33%
C: -7.14%
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 2.89%
H: 0.0%
C: -3.26%
topline therapeutics china phase 1
Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
Published: 2022-03-21 (Crawled : 01:00) - globenewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 4.8%
H: 4.09%
C: 4.09%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: 0.0%
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 10.34%
H: 0.0%
C: 0.0%
zejula pos positive results positive results phase 3 primec
Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer
Published: 2021-11-30 (Crawled : 13:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -7.63%
H: 0.0%
C: 0.0%
chinese treatment positive therapy women results cancer topline phase 3 ovarian cancer primec
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted designation
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Published: 2020-12-17 (Crawled : 02:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 4.86%
H: 0.57%
C: 0.22%
MGNX | $15.62 -2.8% -2.88% 1M
|
Health Technology
|
| O: 11.44%
H: 2.33%
C: -10.52%
fda approval fda approval cancer breast cancer positive her2+ her2- her2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.